Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency: HUMA below $1.00 bid-price requirement for 30 consecutive business days.
- This filing includes Item 3.01, an item that often signal trouble.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq deficiency: HUMA below $1.00 bid-price requirement for 30 consecutive business days
- 180-day cure period through January 27, 2027
- Compliance requires $1.00 closing bid for 10 consecutive business days
- No immediate trading suspension; HUMA remains listed on Nasdaq Global Select Market
- Delisting risk remains if Humacyte fails to regain compliance by the deadline
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.